Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19

Blood blood.2024025010.

https://doi.org/10.1182/blood.2024025010

Published: 2024

Includes: Supplemental data

Journal Articles

Identification of Platelet-Activating Antibodies That Do Not Bind to PF4/Heparin Complexes in Heparin-Induced Thrombocytopenia

Lu Zhou, Daniel Villalobos, Richard H. Aster, Anand Pabmanabhan, Demin Wang, Renren Wen

Blood (2024) 144 (Supplement 1): 5588.

https://doi.org/10.1182/blood-2024-210295

Published: 2024

Journal Articles

A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets

Wen Zhu, Yongwei Zheng, Mei Yu, Nathan Witman, Anand Pabmanabhan, Lisa Baumann Kreuziger, Gilbert C. White, Tongjun Gu, Alexander Fields, Lucy Kornblith, Richard H. Aster, Weiguo Cui, Shawn M. Jobe, Mary Beth Graham, Demin Wang, Renren Wen

Blood (2024) 144 (Supplement 1): 1229.

https://doi.org/10.1182/blood-2024-211524

Published: 2024

Journal Articles

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Bethany Samuelson Bannow, Deepti M. Warad, Curtis G. Jones, Shannon M. Pechauer, Brian R. Curtis, Daniel W. Bougie, Ruchika Sharma, Diane E. Grill, Mary W. Redman, Parisa R. Khalighi, Rachel R. Leger, Rajiv K. Pruthi, Dong Chen, Daniel E. Sabath, Richard H. Aster, David A. Garcia, Anand Padmanabhan

Blood (2021) 137 (8): 1082–1089.

https://doi.org/10.1182/blood.2020008195

Published: 2021

Includes: Supplemental data

Journal Articles

Polyreactivity and Somatic Hypermutation Analysis Reveals the Innate B Cell Origin of Human PF4/Heparin Reactive Antibodies

Wen Zhu, MBBS,MS, Lu Zhou, Ting Zhao, Yongwei Zheng, PhD, Mei Yu, PhD, Jianhui Wei, Anand Padmanabhan, M.B.B.S., PhD, Richard H. Aster, MD, Demin Wang, PhD, Renren Wen, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138781

Published: 2020

Journal Articles

Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies

Nanyan Zhang, Sentot Santoso, Richard H. Aster, Brian R. Curtis, Peter J. Newman

Blood (2019) 134 (22): e1–e8.

https://doi.org/10.1182/blood.2019002225

Published: 2019

Includes: Supplemental data

Journal Articles

The First Case Report of Tazobactam Induced Thrombocytopenia

Minh-Tri H. Nguyen, MD, Pavneet Kaur, MD, Richard H. Aster, MD, Vidya Krishnan, MD MHS

Blood (2019) 134 (Supplement_1): 4897.

https://doi.org/10.1182/blood-2019-126227

Published: 2019

Journal Articles

Cross-Reactivity of Drug-Dependent Antibodies in Patients with Immune Thrombocytopenia Induced By Beta-Lactam Antibiotics

Matthew John Slaught, BS, Daniel W. Bougie, PhD, Richard H. Aster, MD

Blood (2019) 134 (Supplement_1): 2350.

https://doi.org/10.1182/blood-2019-131375

Published: 2019

Journal Articles

Cross-Strain Platelet Immunization in Selected Mouse Strains Recapitulates Clinical and Serologic Findings Typical of Post-Transfusion Purpura (PTP)

Daniel W. Bougie, PhD, Jessica Sutton, Richard H. Aster, MD

Blood (2019) 134 (Supplement_1): 2349.

https://doi.org/10.1182/blood-2019-126815

Published: 2019

Journal Articles

Antibody Cloning Identifies Pathogenic and Non-Pathogenic Antibodies in Heparin-Induced Thrombocytopenia and Defines the Molecular Signatures That Differentiate the Two Types of Antibodies

Wen Zhu, Yongwei Zheng, PhD, Mei Yu, PhD, Yaling Wu, Jianhui Wei, Nicholas Schneider, Anand Padmanabhan, MD PhD, Richard H. Aster, MD, Demin Wang, PhD, Renren Wen, PhD

Blood (2019) 134 (Supplement_1): 439.

https://doi.org/10.1182/blood-2019-126097

Published: 2019

Journal Articles

Serologic Characterization of Antibodies in Patients Experiencing Piperacillin-Induced Immune Thrombocytopenia

Mark Rasmussen, Daniel W. Bougie, PhD, Gregory H. Denomme, Richard H. Aster, MD

Blood (2019) 134 (Supplement_1): 1078.

https://doi.org/10.1182/blood-2019-130966

Published: 2019

Journal Articles

New Monoclonal Antibodies Reveal Distinct Specificities for Platelet Factor 4 Bound to Heparin Vs. Platelets: Implications for HIT Pathogenesis

Anand Padmanabhan, MD PhD, Shannon Pechauer, Curtis Jones, BS, Daniel Bougie, PhD, Richard H. Aster, MD

Blood (2019) 134 (Supplement_1): 1144.

https://doi.org/10.1182/blood-2019-127169

Published: 2019

Journal Articles

Regulatory T Cells Control PF4/Heparin Antibody Production in Mice

Yongwei Zheng, Wen Zhu, Dipica Haribhai, PhD, Calvin B. Williams, PhD, Richard H. Aster, MD, Renren Wen, PhD, Demin Wang, PhD

Blood (2018) 132 (Supplement 1): 2542.

https://doi.org/10.1182/blood-2018-99-113049

Published: 2018

Journal Articles

The Platelet Factor-4 (PF4)-Dependent p-Selectin Expression Assay (PEA) Is Highly Accurate for the Detection of Pathogenic HIT Antibodies: Results of a 440-Sample Prospective Blinded Study

Deepti M. Warad, MD, Bethany T Samuelson Bannow, MD, Curtis Jones, BS, Shannon Pechauer, Brian R. Curtis, PhD, Daniel W. Bougie, PhD, Parisa R Khalighi, BS, Diane E. Grill, MS, Rachel Leger, BAE, Ruchika Sharma, MD, Dong Chen, MD PhD, Richard H. Aster, MD, David A. Garcia, MD, Anand Padmanabhan, MD PhD

Blood (2018) 132 (Supplement 1): 416.

https://doi.org/10.1182/blood-2018-99-112475

Published: 2018

Journal Articles

Use of Intravenous Immunoglobulin G in HIT: Impact on Thrombosis and Mortality in a Population-Based Study

Binod Dhakal, MBBS, Rein Lisa, Aniko Szabo, PhD, Richard H. Aster, MD, Anand Padmanabhan, MD PhD

Blood (2018) 132 (Supplement 1): 2512.

https://doi.org/10.1182/blood-2018-99-117190

Published: 2018

Journal Articles

Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies

Brian R. Curtis, Yen-Michael S. Hsu, Nikolai Podoltsev, Jill Lacy, Susanna Curtis, Michael S. Samuel, Kristin Zutavern, Robert A. DeSimone, Daniel W. Bougie, Richard H. Aster

Blood (2018) 131 (13): 1486–1489.

https://doi.org/10.1182/blood-2017-10-812461

Published: 2018

Includes: Supplemental data

Journal Articles

Normal plasma IgG inhibits HIT antibody–mediated platelet activation: implications for therapeutic plasma exchange

Curtis G. Jones, Shannon M. Pechauer, Brian R. Curtis, Daniel W. Bougie, Richard H. Aster, Anand Padmanabhan

Blood (2018) 131 (6): 703–706.

https://doi.org/10.1182/blood-2017-08-803031

Published: 2018

Includes: Supplemental data

Journal Articles

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Brian R. Curtis, PhDMT(ASCP), Yen-Michael S. Hsu, MD PhD, Nikolai A. Podoltsev, MD PhD, Jill Lacy, MD, Susanna A Curtis, MD, Robert Andrew Desimone, MD, Michael Samuel, MD, Kristin Zutavern, BS, Daniel Bougie, PhD, Richard H. Aster, MD

Blood (2017) 130 (Supplement 1): 3625.

https://doi.org/10.1182/blood.V130.Suppl_1.3625.3625

Published: 2017

Journal Articles

A New Assay for Platelet-Activating HIT Antibodies, the PEA, Is Specific, Reproducible and Relatively Independent of the Choice of Platelet Donor

Shannon Pechauer, Curtis Jones, BS, Daniel W. Bougie, PhD, Brian R. Curtis, PhDMT(ASCP), Richard H. Aster, MD, Anand Padmanabhan, MD PhD

Blood (2017) 130 (Supplement 1): 458.

https://doi.org/10.1182/blood.V130.Suppl_1.458.458

Published: 2017

Journal Articles

Immunoglobulin G in Normal Plasma Inhibits HIT Antibody-Mediated Platelet Activation: Implications for Therapeutic Plasma Exchange Treatment in HIT

Curtis Jones, BS, Shannon Pechauer, Brian R. Curtis, PhDMT(ASCP), Daniel W. Bougie, PhD, Richard H. Aster, MD, Anand Padmanabhan, MD PhD

Blood (2017) 130 (Supplement 1): 2402.

https://doi.org/10.1182/blood.V130.Suppl_1.2402.2402

Published: 2017

NARROW

Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19

Identification of Platelet-Activating Antibodies That Do Not Bind to PF4/Heparin Complexes in Heparin-Induced Thrombocytopenia

A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Polyreactivity and Somatic Hypermutation Analysis Reveals the Innate B Cell Origin of Human PF4/Heparin Reactive Antibodies

Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies

The First Case Report of Tazobactam Induced Thrombocytopenia

Cross-Reactivity of Drug-Dependent Antibodies in Patients with Immune Thrombocytopenia Induced By Beta-Lactam Antibiotics

Cross-Strain Platelet Immunization in Selected Mouse Strains Recapitulates Clinical and Serologic Findings Typical of Post-Transfusion Purpura (PTP)

Antibody Cloning Identifies Pathogenic and Non-Pathogenic Antibodies in Heparin-Induced Thrombocytopenia and Defines the Molecular Signatures That Differentiate the Two Types of Antibodies

Serologic Characterization of Antibodies in Patients Experiencing Piperacillin-Induced Immune Thrombocytopenia

New Monoclonal Antibodies Reveal Distinct Specificities for Platelet Factor 4 Bound to Heparin Vs. Platelets: Implications for HIT Pathogenesis

Regulatory T Cells Control PF4/Heparin Antibody Production in Mice

The Platelet Factor-4 (PF4)-Dependent p-Selectin Expression Assay (PEA) Is Highly Accurate for the Detection of Pathogenic HIT Antibodies: Results of a 440-Sample Prospective Blinded Study

Use of Intravenous Immunoglobulin G in HIT: Impact on Thrombosis and Mortality in a Population-Based Study

Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies

Normal plasma IgG inhibits HIT antibody–mediated platelet activation: implications for therapeutic plasma exchange

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

A New Assay for Platelet-Activating HIT Antibodies, the PEA, Is Specific, Reproducible and Relatively Independent of the Choice of Platelet Donor

Immunoglobulin G in Normal Plasma Inhibits HIT Antibody-Mediated Platelet Activation: Implications for Therapeutic Plasma Exchange Treatment in HIT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only